We currently have a number of license agreements with various pharmaceutical and biotechnology companies.  These companies are pursuing the development of product candidates that were generated by our internal research and discovery efforts or were licensed by us. We have outlicensed product candidates when we believed the program was not a strategic fit for our portfolio development strategy. In the future, if our licencees achieve operational milestones, these existing agreements may generate potential milestone payments and future royalties if the licensed product candidates are approved for marketing.
Learn more about our licensing agreements with each of these companies: 

Abbott Laboratories, Inc.

In 2003, we and Abbott entered into a licensing agreement that provides Abbott certain rights to intellectual property related to fully human antibodies capable of binding interleukin-12 (IL-12) or its receptor. Abbott has announced that its anti-IL-12 biologic, ABT-874, is in phase 3 development for psoriasis. ABT-874 is also in early studies for Crohn's disease.

Actinium Pharmaceuticals, Inc.

In 2003, we licensed HuM195, an anti-CD33 antibody, to Actinium. Actinium has announced that it is conducting ongoing clinical development activities to support HuM195.

EKR Therapeutics, Inc.

In 2008, we entered into an agreement with EKR for the sale of our cardiovascular assets, including a currently marketed antihypertensive product, Cardene, and the development product, ularitide. Under the agreement, we are entitled to milestones and royalties related to future sales of pre-mixed bag formulations of Cardene and to royalties related to future sales of ularitide.    

Genentech, Inc.

In 2005, we entered into an agreement with Genentech to sub-license development and commercialization rights to Genentech for antibody-drug conjugates (ADC) directed against the TMEFF2 antigen, which is frequently differentially expressed in prostate cancer. Prior to the agreement, our scientists conducted preclinical work to validate the target and characterize the antibody. We believe that Genentech continues clinical development activities to support this antibody.

Ophthotech Corporation

In 2008, we and Biogen Idec entered into an exclusive worldwide licensing agreement with Ophthotech, a privately held biopharmaceutical company focused on developing ophthalmic therapies for back-of-the-eye diseases, for our volociximab antibody to treat age-related macular degeneration (AMD). Under the agreement, Ophthotech was granted worldwide development and commercial rights to all ophthalmic uses of volociximab. We believe Ophthotech continues its research efforts and that it intends to advance volociximab into clinical testing in the near future.

Progenics Pharmaceuticals, Inc.

In 1999, we entered into a humanization agreement with Progenics whereby we humanized an antibody targeted to the CCR5 receptor (designed by Progenics as PRO 140). Progenics recently completed a phase 1b study of PRO 140, its principal HIV drug candidate.  Effective on the distribution date, we anticipate that PDL will distribute to us this licensing agreement.   Progenics’ consent is required in connection with this assignment, and we are in the process of seeking such consent.

Seattle Genetics, Inc.

In 2005, Seattle Genetics exclusively licensed rights to our anti-CD33 program for both unconjugated antibody and antibody-drug conjugate (ADC) applications. Seattle Genetics is conducting phase 1 and phase 2 clinical development of SGN-33 (lintuzumab), a humanized monoclonal antibody that targets the CD33 antigen, in patients with acute myeloid leukemia or myeloid displastic syndrome.  Seattle Genetics has received orphan drug designation from the FDA for SGN-33 in both diseases. In 2007, Seattle Genetics also licensed rights from us to another preclinical target.

Our Pipeline
R&D
Careers at Facet Biotech